Bromelain is a protease obtained from various species of Bromeliaceae family, which is present on the stem and fruit. It is used in food and pharmaceutical industries based on its proteolytic activity. Bromelain is known for its clinical and therapeutic applications, particularly for the modulation of tumor growth, selective debridement of burns and improved antibiotic and anti-inflammatory action, and antithrombotic and fibrinolytic activities. The polymeric nanoparticles have been intensively researched as promising drug delivery systems. These systems are able to provide greater stability, efficacy and safety for the encapsulated active and have attracted the interest of the pharmaceutical industry. In this scenario, chitosan is emerging as a promising polymer, mainly due to its biocompatible, biodegradable and mucus adherence characteristics. This project aims to develop chitosan-bromelain nanoparticles, which can be highly promising from scientific and technological points of view. In addition, the project also aims the pharmacological activity and toxicity evaluation in vitro of the developed nanoparticles.
News published in Agência FAPESP Newsletter about the scholarship: